Cancer of the Head and Neck Clinical Trial
— RadioHumOfficial title:
A Randomised Phase III Trial of Radiotherapy With Humidification in Head And Neck Cancer
Verified date | July 2017 |
Source | Trans-Tasman Radiation Oncology Group (TROG) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a two arm randomised phase III trial which will evaluate prospectively the benefits of humidification in patients receiving radiotherapy / chemoradiation for head and neck cancer. The intent of humidification is to moisturise the mucosa. The rationale for the use of humidification with radiotherapy can be considered an extension of the general principle of moist wound care in wound management.
Status | Completed |
Enrollment | 210 |
Est. completion date | August 2013 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients who meet the following criteria will be eligible: - Pathologically confirmed diagnosis of cancer involving the Nasopharynx, Oropharynx, Oral Cavity, Larynx, or Hypopharynx - Regional nodal irradiation included in PTV1 (as a minimum ipsilateral levels II-III) - Prescribed dose of radiotherapy is at least 60 Gy - Receiving definitive or post-operative adjuvant Radiotherapy - Receiving Radiotherapy as sole modality or Chemoradiation - Patient > 18 years old - Available for follow-up for up to 2 years - Life expectancy greater than 6 months - Written informed consent - Participation of patients on other clinical trial protocols permitted Exclusion Criteria: Patients who meet the following criteria will be excluded: - Presence of tracheostomy or stoma - Diagnosis of T1 / T2 glottic carcinoma - Undergoing CPAP therapy -Treatment with Amifostine or Palifermin (keratinocyte growth factor) during radiotherapy - History of previous radiotherapy to the head and neck region, excluding superficial radiotherapy to cutaneous squamous cell carcinoma or basal cell carcinoma - High risk for poor compliance with radiotherapy, humidification, or follow-up as assessed by the investigator |
Country | Name | City | State |
---|---|---|---|
New Zealand | Auckland Hospital | Auckland |
Lead Sponsor | Collaborator |
---|---|
Trans-Tasman Radiation Oncology Group (TROG) | Auckland City Hospital, Fisher and Paykel Healthcare |
New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intensity of mucositis as a function of time for CTCAE grade > 1 mucositis (e.g. grade 2 or higher) measured as the area under the time curve (AUC) of the plot expressing grade of acute reactions vs weeks for observed CTCAE mucosal reactions > 1. | week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04444869 -
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
|
Phase 2 | |
Terminated |
NCT01370876 -
Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT03297957 -
Fluorescence Imaging in Head and Neck Cancer
|
N/A | |
Completed |
NCT00716157 -
Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation
|
N/A | |
Recruiting |
NCT04880148 -
The Effectiveness of a Thyme and Honey Spray for Oral Toxicities
|
N/A | |
Completed |
NCT01017224 -
DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC)
|
N/A | |
Completed |
NCT00798655 -
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00496652 -
DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
|
Phase 3 | |
Recruiting |
NCT03620084 -
Effects of Expiratory Muscle Strength Training on Airway Protection and Swallowing in Chronic Dysphagia After Radiation Therapy
|
N/A | |
Completed |
NCT00147472 -
Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial)
|
Phase 3 | |
Completed |
NCT02880072 -
Absorption of Orally Ingested Phosphate in Refeeding Syndrome
|
Phase 4 | |
Recruiting |
NCT04865731 -
Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT02442336 -
A Web-Based Multimedia Intervention for Head and Neck Cancer Patients
|
N/A | |
Completed |
NCT03102229 -
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
|
N/A | |
Completed |
NCT00474825 -
Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
Recruiting |
NCT00180921 -
Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
Completed |
NCT01283334 -
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT02557048 -
Head and Neck Cancer in Children: A Retrospective Study
|
||
Completed |
NCT02073032 -
Incidence and Risk Factors of Refeeding Syndrome
|
N/A | |
Active, not recruiting |
NCT02270814 -
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
|
Phase 2 |